TMEFF2 modulates the AKT and ERK signaling pathways

International Journal of Biochemistry and Molecular Biology

Volumn 4, Issue 2, 2013, Pages 83-94

  Chen, Xiaofei ^a   Ruiz Echevarría, Maria J ^a,b  

^a EAST CAROLINA UNIVERSITY   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

AKT; ERK; Phosphorylation; Prostate cancer; Signaling pathways; TMEFF2

Indexed keywords

EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 4; FOLLISTATIN; G PROTEIN COUPLED RECEPTOR; MEMBRANE PROTEIN; METALLOPROTEINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLATELET DERIVED GROWTH FACTOR; PROTEIN KINASE; RAF PROTEIN; RAS PROTEIN; TETRAHYDROFOLIC ACID; TMEFF2 PROTEIN; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; CANCER GROWTH; HUMAN; HUMAN CELL; MOLECULAR MECHANICS; PROSTATE CANCER; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; TUMOR GROWTH;

EID: 84881512898     PISSN: None     EISSN: 21524114     Source Type: Journal    
DOI: None     Document Type: Article

References (48)

1. Siegel R, Ward E, Brawley O, Jemal A. Cancer statistics, 2011: The impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 2011; 61: 212-236.
2. Karantanos T, Corn PG, Thompson TC. Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 2013; doi: 10.1038/onc.2013.206. [Epub ahead of print].
3. Kinkade CW, Castillo-Martin M, Puzio-Kuter A, Yan J, Foster TH, Gao H, Sun Y, Ouyang X, Gerald WL, Cordon-Cardo C, Abate-Shen C. Targeting AKT/mTOR and ERK MAPK signaling inhibits hormone-refractory prostate cancer in a preclinical mouse model. J Clin Invest 2008; 118: 3051-3064.
4. Grant S. Cotargeting survival signaling pathways in cancer. J Clin Invest 2008; 118: 3003-3006.
5. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, Navolanic PM, Terrian DM, Franklin RA, D'Assoro AB, Salisbury JL, Mazzarino MC, Stivala F, Libra M. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 2006; 46: 249-279.
6. Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci 2011; 36: 320-328.
7. Moelling K, Schad K, Bosse M, Zimmermann S, Schweneker M. Regulation of Raf-Akt crosstalk. J Biol Chem 2002; 277: 31099-31106.
8. Bartholomeusz C, Gonzalez-Angulo AM, Liu P, Hayashi N, Lluch A, Ferrer-Lozano J, Hortobá-gyi GN. High ERK. Protein expression levels correlate with shorter survival in triple-negative breast cancer patients. Oncologist 2012; 17: 766-774.
9. Gee JM, Robertson JF, Ellis IO, Nicholson R. Phosphorylation of ERK1/2 mitogen-activated protein kinase is associated with poor response to anti-hormonal therapy and decreased patient survival in clinical breast cancer. Int J Cancer 2001; 95: 247-254.
10. Kress TR, Raabe T, Feller SM. High Erk activity suppresses expression of the cell cycle inhibitor p27Kip1 in colorectal cancer cells. Cell Commun Signal 2010; 8: 1.
11. Malik SN, Brattain M, Ghosh PM, Troyer DA, Prihoda T, Bedolla R, Kreisberg JI. Immunohis-tochemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 2002; 8: 1168-1171.
12. Heanue TA, Pachnis V. Expression profling the developing mammalian enteric nervous system identifes marker and candidate Hirschs-prung disease genes. Proc Natl Acad Sci USA 2006; 103: 6919-6924.
13. Uchida T, Wada K, Akamatsu T, Yonezawa M, Noguchi H, Mizoguchi A, Kasuga M, Sakamoto C. A novel epidermal growth factor-like molecule containing two follistatin modules stimulates tyrosine phosphorylation of erbB-4 in MKN28 gastric cancer cells. Biochem Biophys Res Commun 1999; 266: 593-602.
14. Afar DE, Bhaskar V, Ibsen E, Breinberg D, Hen-shall SM, Kench JG, Drobnjak M, Powers R, Wong M, Evangelista F, O'Hara C, Powers D, DuBridge RB, Caras I, Winter R, Anderson T, Solvason N, Stricker PD, Cordon-Cardo C, Scher HI, Grygiel JJ, Sutherland RL, Murray R, Ramakrishnan V, Law DA. Preclinical validation of anti-TMEFF2-auristatin E-conjugated antibodies in the treatment of prostate cancer. Mol Cancer Ther 2004; 3: 921-932.
15. Gery S, Sawyers CL, Agus DB, Said JW, Koeffer HP. TMEFF2 is an androgen-regulated gene exhibiting antiproliferative effects in prostate cancer cells. Oncogene 2002; 21: 4739-4746.
16. Glynne-Jones E, Harper ME, Seery LT, James R, Anglin I, Morgan HE, Taylor KM, Gee JM, Nicholson RI. TENB2, a proteoglycan identifed in prostate cancer that is associated with disease progression and androgen independence. Int J Cancer 2001; 94: 178-184.
17. Horie M, Mitsumoto Y, Kyushiki H, Kanemoto N, Watanabe A, Taniguchi Y, Nishino N, Oka-moto T, Kondo M, Mori T, Noguchi K, Nakamu-ra Y, Takahashi E, Tanigami A. Identification and characterization of TMEFF2, a novel survival factor for hippocampal and mesencephal-ic neurons. Genomics 2000; 67: 146-152.
18. Ali N, Knauper V. Phorbol ester-induced shedding of the prostate cancer marker transmem-brane protein with epidermal growth factor and two follistatin motifs 2 is mediated by the disintegrin and metalloproteinase-17. J Biol Chem 2007; 282: 37378-37388.
19. Lin H, Wada K, Yonezawa M, Shinoki K, Aka-matsu T, Tsukui T, Sakamoto C. Tomoregulin ectodomain shedding by proinfammatory cyto-kines. Life Sci 2003; 73: 1617-1627.
20. Eib DW, Martens GJ. A novel transmembrane protein with epidermal growth factor and fol-listatin domains expressed in the hypothala-mo-hypophysial axis of Xenopus laevis. J Neu-rochem 1996; 67: 1047-1055.
21. Mohler JL, Morris TL, Ford OH, Alvey RF, Sakamoto C, Gregory CW. Identification of differentially expressed genes associated with andro-gen-independent growth of prostate cancer. Prostate 2002; 51: 247-255.
22. Chen X, Overcash R, Green T, Hoffman D, Asch AS, Ruiz-Echevarria MJ. The tumor suppressor activity of the transmembrane protein with epidermal growth factor and two follistatin motifs 2 (TMEFF2) correlates with its ability to modulate sarcosine levels. J Biol Chem 2011; 286: 16091-16100.
23. Green T, Chen X, Ryan S, Asch A, Ruiz-Echevar-ria MJ. TMEFF2 and SARDH cooperate to modulate one carbon metabolism and invasion of prostate cancer cells. Prostate 2013; doi: 10.1002/pros.22706. [Epub ahead of print].
24. Elahi A, Zhang L, Yeatman TJ, Gery S, Sebti S, Shibata D. HPP1-mediated tumor suppression requires activation of STAT1 pathways. Int J Cancer 2008; 122: 1567-1572.
25. Horie M, Mitsumoto Y, Kyushiki H, Kanemoto N, Watanabe A, Taniguchi Y, Nishino N, Oka-moto T, Kondo M, Mori T, Noguchi K, Nakamu-ra Y, Takahashi E, Tanigami A. Identification and characterization of TMEFF2, a novel survival factor for hippocampal and mesencephal-ic neurons. Genomics 2000; 67: 146-152.
26. Lin K, Taylor JR, Wu TD, Gutierrez J, Elliott JM, Vernes JM, Koeppen H, Phillips HS, de Sau-vage FJ, Meng YG. TMEFF2 is a PDGF-AA binding protein with methylation-associated gene silencing in multiple cancer types including glioma. PLoS One 2011; 6: e18608.
27. Quayle SN, Sadar MD. A truncated isoform of TMEFF2 encodes a secreted protein in prostate cancer cells. Genomics 2006; 87: 633-637.
28. Park YH, Seo SY, Ha M, Ku JH, Kim HH, Kwak C. Inhibition of prostate cancer using RNA interference-directed knockdown of platelet-derived growth factor receptor. Urology 2011; 77: 1509.
29. Moelling K, Schad K, Bosse M, Zimmermann S, Schweneker M. Regulation of Raf-Akt Crosstalk. J Biol Chem 2002; 277: 31099-31106.
30. Reusch HP, Zimmermann S, Schaefer M, Paul M, Moelling K. Regulation of Raf by Akt controls growth and differentiation in vascular smooth muscle cells. J Biol Chem 2001; 276: 33630-33670.
31. Chang C, Eggen BJ, Weinstein DC, Brivanlou AH. Regulation of nodal and BMP signaling by tomoregulin-1 (X7365) through novel mechanisms. Dev Biol 2003; 255: 1-11.
32. Harms PW, Chang C. Tomoregulin-1 (TMEFF1) inhibits nodal signaling through direct binding to the nodal coreceptor Cripto. Genes Dev 2003; 17: 2624-2629.
33. Boswell CA, Mundo EE, Zhang C, Stainton SL, Yu SF, Lacap JA, Mao W, Kozak KR, Fourie A, Polakis P, Khawli LA, Lin K. Differential effects of predosing on tumor and tissue uptake of an 111In-labeled anti-TENB2 antibody-drug conjugate. J Nucl Med 2012; 53: 1454-1461.
34. Zhao XY, Schneider D, Biroc SL, Parry R, Alicke B, Toy P, Xuan JA, Sakamoto C, Wada K, Schul-ze M, Muller-Tiemann B, Parry G, Dinter H. Targeting tomoregulin for radioimmunotherapy of prostate cancer. Cancer Res 2005; 65: 2846-2850
35. Zimmermann S, Moelling K. Phosphorylation and regulation of Raf by Akt (protein kinase B). Science 1999; 286: 1741-1744
36. Er EE, Mendoza MC, Mackey AM, Rameh LE, Blenis J. AKT Facilitates EGFR Trafficking and Degradation by Phosphorylating and Activating PIKfyve. Sci Signal 2013; 6: ra45. doi: 10.112-6/scisignal.2004015.
37. Chow LM, Baker SJ. PTEN function in normal and neoplastic growth. Cancer Lett 2006; 241: 184-196.
38. Malik SN, Brattain M, Ghosh PM, Troyer DA, Pri-hoda T, Bedolla R, Kreisberg JI. Immunohisto-chemical demonstration of phospho-Akt in high Gleason grade prostate cancer. Clin Cancer Res 2002; 8: 1168-1171.
39. Kreisberg JI, Malik SN, Prihoda TJ, Bedolla RG, Troyer DA, Kreisberg S, Ghosh PM. Phosphory-lation of Akt (Ser473) is an excellent predictor of poor clinical outcome in prostate cancer. Cancer Res 2004; 64: 5232-5236.
40. Graff JR, Konicek BW, McNulty AM, Wang Z, Houck K, Allen S, Paul JD, Hbaiu A, Goode RG, Sandusky GE, Vessella RL, Neubauer BL. Increased AKT activity contributes to prostate cancer progression by dramatically accelerating prostate tumor growth and diminishing p27Kip1 expression. J Biol Chem 2000; 275: 24500-24505.
41. Deschênes-Simard X, Gaumont-Leclerc MF, Bourdeau V, Lessard F, Moiseeva O, Forest V, Igelmann S, Mallette FA, Saba-El-Leil MK, Meloche S, Saad F, Mes-Masson AM, Ferbeyre G. Tumor suppressor activity of the ERK/MAPK pathway by promoting selective protein degradation. Genes Dev 2013; 27: 900-915.
42. Labeur M, Wölfel B, Panhuysen M, Stalla J, Stalla GK, Paez-Pereda M. TMEFF2: a new endogenous modulator of the CRH signaling in corticotroph cells. Exp Clin Endocrinol Diabetes 2010; 118-213. DOI: 10.1055/s-0030-12-67015.
43. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, Laxman B, Mehra R, Lo-nigro RJ, Li Y, Nyati MK, Ahsan A, Kalyana-Sun-daram S, Han B, Cao X, Byun J, Omenn GS, Ghosh D, Pennathur S, Alexander DC, Berger A, Shuster JR, Wei JT, Varambally S, Beecher C, Chinnaiyan AM. Metabolomic profles delineate potential role for sarcosine in prostate cancer progression. Nature 2009; 457: 910-914.
44. Fox JT, Stover PJ. Folate-mediated one-carbon metabolism. Vitam Horm 2008; 79: 1-44.
45. Lee SJ, Lee YS, Seo KW, Bae JU, Kim GH, Park SY, Kim CD. Homocysteine enhances MMP-9 production in murine macrophages via ERK and Akt signaling pathways. Toxicol Appl Pharmacol 2012; 260: 89-94.
46. Xin L, Teitell MA, Lawson DA, Kwon A, Melling-hoff IK, Witte ON. Progression of prostate cancer by synergy of AKT with genotropic and non-genotropic actions of the androgen receptor. Proc Natl Acad Sci U S A 2006; 103: 7789-7794.
47. Lin HK, Yeh S, Kang HY, Chang C. Akt suppresses androgen-induced apoptosis by phosphory-lating and inhibiting androgen receptor. Proc Natl Acad Sci USA 2001; 98: 7200-7205.
48. Overcash R, Chappell V, Green T, Geyer C, Asch A, Ruiz-Echevarría M. Androgen signaling promotes translation of TMEFF2 in prostate cancer cells via phosphorylation of the alpha sub-unit of the translation initiation factor 2 (eIF2α). PLoS One 2013; e55257.